These limitations can be overcome by fusing TRAIL to tumor-specific antibodies or antibody-fragments, particularly constructs based on IgG structures (IgG-like), which generally harbor a superior pharmacokinetic profile [20,37,38]. The gene discussed is TNFSF10; the disease is neoplasm.